These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38365599)

  • 1. Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.
    Collier W; Haaland B; Inker LA; Heerspink HJL; Greene T
    BMC Med Res Methodol; 2024 Feb; 24(1):39. PubMed ID: 38365599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.
    Papanikos T; Thompson JR; Abrams KR; Städler N; Ciani O; Taylor R; Bujkiewicz S
    Stat Med; 2020 Apr; 39(8):1103-1124. PubMed ID: 31990083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the Estimation of Subgroup Effects for Clinical Trial Participants with Multimorbidity by Incorporating Drug Class-Level Information in Bayesian Hierarchical Models: A Simulation Study.
    Hannigan LJ; Phillippo DM; Hanlon P; Moss L; Butterly EW; Hawkins N; Dias S; Welton NJ; McAllister DA
    Med Decis Making; 2022 Feb; 42(2):228-240. PubMed ID: 34407672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.
    Bujkiewicz S; Thompson JR; Spata E; Abrams KR
    Stat Methods Med Res; 2017 Oct; 26(5):2287-2318. PubMed ID: 26271918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling heterogeneity variances in multiple treatment comparison meta-analysis--are informative priors the better solution?
    Thorlund K; Thabane L; Mills EJ
    BMC Med Res Methodol; 2013 Jan; 13():2. PubMed ID: 23311298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.
    Curtis A; Smith B; Chapple AG
    Stat Med; 2022 Jul; 41(16):3164-3179. PubMed ID: 35429178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivariate network meta-analysis for surrogate endpoint evaluation.
    Bujkiewicz S; Jackson D; Thompson JR; Turner RM; Städler N; Abrams KR; White IR
    Stat Med; 2019 Aug; 38(18):3322-3341. PubMed ID: 31131475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis.
    Badve SV; Palmer SC; Strippoli GFM; Roberts MA; Teixeira-Pinto A; Boudville N; Cass A; Hawley CM; Hiremath SS; Pascoe EM; Perkovic V; Whalley GA; Craig JC; Johnson DW
    Am J Kidney Dis; 2016 Oct; 68(4):554-563. PubMed ID: 27138469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
    Lassere MN; Johnson KR; Schiff M; Rees D
    BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.
    Wheaton L; Papanikos A; Thomas A; Bujkiewicz S
    Med Decis Making; 2023 Jul; 43(5):539-552. PubMed ID: 36998240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.
    Heerspink HJL; Greene T; Tighiouart H; Gansevoort RT; Coresh J; Simon AL; Chan TM; Hou FF; Lewis JB; Locatelli F; Praga M; Schena FP; Levey AS; Inker LA;
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):128-139. PubMed ID: 30635226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogacy assessment using principal stratification with multivariate normal and Gaussian copula models.
    Taylor JM; Conlon AS; Elliott MR
    Clin Trials; 2015 Aug; 12(4):317-22. PubMed ID: 25490988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian meta-analysis for evaluating treatment effectiveness in biomarker subgroups using trials of mixed patient populations.
    Wheaton L; Jackson D; Bujkiewicz S
    Res Synth Methods; 2024 Jul; 15(4):543-560. PubMed ID: 38316618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating expert opinions with clinical trial data to analyse low-powered subgroup analyses: a Bayesian analysis of the VeRDiCT trial.
    Thirard R; Ascione R; Blazeby JM; Rogers CA
    BMC Med Res Methodol; 2020 Dec; 20(1):300. PubMed ID: 33302878
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.